How Should Genetic Counseling for Ovarian Cancer Be Implemented in a Middle-Income Country? An Insight Based on the Brazilian Scenario

Our aim is to focus attention on epithelial ovarian cancer (EOC), a serious health problem and a burden for women in Brazil. Ovarian cancer is the seventh most common cancer among Brazilian women and one of the deadliest, with 3,320 deaths in 2014 and estimates of 6,150 new cases in 2016. Unfortunately, in most parts of the world, 5-year survival for patients with ovarian cancer is dismal, in the range of 30% to 40%, mainly because the disease has already reached an advanced stage at first diagnosis.

One of the main risk factors for EOC is a germline mutation in the BRCA1 or BRCA2 genes, which account for approximately 6% to 24% of EOC cases worldwide. In two recent studies performed among Brazilian patients with EOC, about one fifth were BRCA1 or BRCA2 mutation carriers. Women harboring BRCA1/2 germ line mutations have an increased lifetime risk of EOC, with risk estimates of up to 59% for BRCA1 carriers and 35% for BRCA2 carriers. Patients with EOC who are BRCA1 or BRCA2 mutation carriers may benefit from targeted therapies. Their healthy family members who are BRCA1 or BRCA2 mutation carriers may also benefit from early detection measures for breast cancer as well as from preventive measures for both ovarian and breast cancer. An additional 6% of unselected patients with ovarian cancer may have mutations in other cancer-predisposing genes such as BARD1, CHEK2, MRE11A, MSH6, NBN, PALB2, RAD50, RAD51C, RAD51, and TP53. For these reasons, a diagnosis of EOC should be considered an indication for multigene testing.

In Brazil, there is a dual composite system of public and private health care, and even though one fourth of the population contributes to private health care insurance, the remaining three fourths depends exclusively on the public health care system, Sistema Único de Saúde (SUS). SUS was instituted in the 7th Brazilian Federal Constitution in 1988, which states that health is a right of each citizen and the duty of the state, which should guarantee universal access to health promotion, health protection, and health care. There are approximately 207,700,000 people in Brazil, which makes SUS one of the biggest public health care systems in the world. In Brazil in the twenty-first century, despite the benefits stated before, it is not common practice in the public health care system to screen women who have a diagnosis of EOC for the presence of germ line mutations, mainly because there are no facilities to perform this genetic testing.

We believe a public testing facility should be made available to offer genetic testing to all women with a recent diagnosis of EOC and we propose a model for a centralized facility dedicated to next-generation sequencing (NGS) to process samples. We think this is feasible because the costs of multigene testing by NGS are rapidly decreasing. In this model, physicians would invite all women diagnosed with EOC to have genetic testing. After obtaining a signed informed consent, the women would complete a questionnaire regarding demographic information, clinical data, and family history of cancer. A sample provided via oral swab would then be collected. All this material (accompanied by the histopathologic report) would be sent by express mail to the central facility, where a first triage would be made by health professionals to confirm the histopathology diagnosis and the indication for mutation testing. DNA would be extracted from the oral swab and analyzed through NGS by using a multigene panel to identify gene variants and also through multiplex ligation-dependent probe amplification to detect
major rearrangements. A consulting oncogeneticist would review the sequencing reports and the results would be sent to the assisting physicians. Patients who are BRCA1 or BRCA2 mutation carriers would be referred for genetic counseling. In this model, one facility and one dedicated team specializing in molecular biology and genetics would suffice. We propose to apply a gene panel sequencing assay featuring genes that might be altered in ovarian cancer and we consider the cost of our plan to be reasonable (Table 1).

In summary, a diagnosis of EOC is strongly associated with germ line mutations. Although it is still expensive for our health care system (for comparison, the minimum monthly wage in Brazil was $371.00 [USD] in 2016),9 multigene testing of patients with EOC might greatly benefit healthy family members who carry the same gene mutation and who might adopt preventive measures to avoid cancer.

DOI: https://doi.org/10.1200/JGO.17.00230
Published online on jgo.org on March 28, 2018.

AUTHOR CONTRIBUTIONS
Conception and design: Maria Aparecida Azevedo Koike Folgueira, Simone Maistro, Natalia Teixeira, Geertruida de Bock
Provision of study materials or patients: Simone Maistro, Natalia Teixeira
Collection and assembly of data: Maria Aparecida Azevedo Koike Folgueira, Simone Maistro
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/hwc or ascopubs.org/jco/site/ifc.

Maria Aparecida Azevedo Koike Folgueira
No relationship to disclose

Simone Maistro
No relationship to disclose

Natalia Teixeira
No relationship to disclose

Marian J.E. Mourits
No relationship to disclose

Roger Chammas
No relationship to disclose

Geertruida Hendrika De Bock
No relationship to disclose

ACKNOWLEDGMENT
Supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico Grant No. 307651/2014-2 (M.A.A.K.F.), by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Programa Pesquisador Visitante Especial (PVE) Grant No. PVE 029/2012 (G.H.d.B.), by CAPES postdoctoral scholarship Grant No. PVE 029/2012 (S.M.), and by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) scholarship Grants No. 2012/05754-1 (N.T.) and No. 2017/02389-3 (M.A.A.K.F.).

Table 1. Model for a Gene Testing Facility

<table>
<thead>
<tr>
<th>Factors</th>
<th>Proposal and Cost Estimates</th>
</tr>
</thead>
<tbody>
<tr>
<td>The team</td>
<td>We propose a dedicated team that includes seven health professionals: four biomedicals or biologists or pharmacists, one oncogeneticist, and two laboratory technicians.</td>
</tr>
<tr>
<td>The facility</td>
<td>We propose a facility with one automated DNA extraction system, one fluorometer for DNA quantitation, one automated system for DNA quality control, one NGS system capable of analyzing at least 24 samples per day, and one capillary sequencing instrument (for MLPA and for capillary sequencing of an identified pathogenic mutation in family members).</td>
</tr>
<tr>
<td>Estimated costs</td>
<td>We estimate $142.00 (USD) per patient for multigene testing: a gene panel sequencing assay (approximately $52.00 per sample) plus reagents and flow cell (approximately $32.00 per sample) and MLPA kit and reagents (approximately $58.00 per sample), which adds up to $284.00. These values do not include Brazilian import taxes or staff wages and facility maintenance.</td>
</tr>
</tbody>
</table>

Abbreviations: MLPA, multiplex ligation-dependent probe amplification; NGS, next-generation sequencing.
Affiliations
Maria Aparecida Azevedo Koike Folgueira, Simone Maistro, and Roger Chammas, Instituto do Cancer do Estado de Sao Paulo (ICESP), Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil; Natalia Teixeira, Marian J.E. Mourits, and Geertruida Hendrika de Bock, University of Groningen, Groningen, the Netherlands

REFERENCES
1. Brazil, Ministério da Saúde, Instituto Nacional de Câncer: Mortalidade proporcional não ajustada por câncer, Brasil ou Região, homens, mulheres ou homens e mulheres, groupCid e por ano ou período selecionado. 2017. https://mortalidade.inca.gov.br/MortalidadeWeb/pages/Modelo01/consultar.xhtml;jsessionid=929E564957AAAF5797B600F51AC86FEBA#panelResultado


